Tempus Wealth Planning LLC Has $222,000 Stock Holdings in CVS Health Co. (NYSE:CVS)

Tempus Wealth Planning LLC lessened its position in shares of CVS Health Co. (NYSE:CVS) by 60.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,783 shares of the pharmacy operator’s stock after selling 4,217 shares during the quarter. Tempus Wealth Planning LLC’s holdings in CVS Health were worth $222,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CVS. Atticus Wealth Management LLC lifted its stake in shares of CVS Health by 149.0% during the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after acquiring an additional 219 shares during the period. USA Financial Formulas lifted its stake in CVS Health by 573.2% in the fourth quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock valued at $30,000 after buying an additional 321 shares during the period. Ables Iannone Moore & Associates Inc. acquired a new position in CVS Health in the fourth quarter valued at about $32,000. Creekmur Asset Management LLC acquired a new position in CVS Health in the fourth quarter valued at about $34,000. Finally, Steph & Co. increased its holdings in shares of CVS Health by 192.0% in the first quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock worth $35,000 after acquiring an additional 288 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity

In other CVS Health news, Director Edward J. Ludwig purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were bought at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the purchase, the director now owns 21,630 shares in the company, valued at approximately $1,165,424.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.24% of the company’s stock.

CVS Health Price Performance

CVS Health stock opened at $56.70 on Friday. The stock’s fifty day moving average price is $58.68 and its two-hundred day moving average price is $69.71. CVS Health Co. has a one year low of $52.77 and a one year high of $83.25. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. The firm has a market cap of $71.18 billion, a PE ratio of 9.96, a price-to-earnings-growth ratio of 0.54 and a beta of 0.52.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The company had revenue of $88.44 billion for the quarter, compared to the consensus estimate of $89.33 billion. During the same quarter last year, the business earned $2.20 EPS. CVS Health’s revenue was up 3.7% on a year-over-year basis. As a group, research analysts expect that CVS Health Co. will post 7.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CVS. Truist Financial restated a “buy” rating and issued a $66.00 price target (down from $90.00) on shares of CVS Health in a report on Thursday, May 2nd. Argus decreased their price objective on CVS Health from $100.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Robert W. Baird began coverage on CVS Health in a report on Thursday, May 30th. They set a “neutral” rating and a $61.00 price objective for the company. Bank of America decreased their price objective on CVS Health from $95.00 to $77.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Finally, Mizuho decreased their price objective on CVS Health from $86.00 to $72.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $75.05.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.